The Chumakov Center COVID-19 Vaccine Will Be Used after Clinical Trials are Completed

06 October 2020

GMP News

The anti-coronavirus vaccine, developed by Russia’s Chumakov Center can be used immediately after it successfully passes all clinical trials, scheduled for completion in November, the center’s Director General Ildar Ishmukhametov has told TASS.

“Certainly, we will be able to start using it immediately after completing all clinical trials. We plan to complete them in November,” he said.

President of the Russian Academy of Sciences Alexander Sergeyev told in late September that the Chumakov Center’s vaccine rests on the century-long global and domestic experience of work with whole-virion vaccines and may have a serious export potential. “It implies work with the virus causing a disease, but this virus id dead, harmless, inactive. I must say that most of the world nations typically use such whole-virion vaccines against various diseases. Such viruses are not hazardous but vaccines on their basis prompt good immune response,” he added.

According to the Russian scientist, the Chumakov Center has a modern production facility with the capacity to produce up to ten million doses of various vaccines.

The Russian health ministry has issued a permit for clinical trials of the Chumakov Center’s vaccine and the tests will soon begin in Kirov, St. Petersburg, and Novosibirsk and will involve more than 3,000 volunteers. According to the Center’s director general, Aidar Ishmukhametov, clinical tests are scheduled to be completed in November.

Source

Print

Shareholders

Read more

Pipeline

Read more

Media Center

Read more